Literature DB >> 7708691

Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells.

K M Weidner1, M Sachs, D Riethmacher, W Birchmeier.   

Abstract

Signals transduced by the met tyrosine kinase, which is the receptor for scatter factor/hepatocyte growth factor, are of major importance for the regulation of epithelial cell motility, morphogenesis, and proliferation. We report here that different sets of tyrosine residues in the cytoplasmic domain of the met receptor affect signal transduction in epithelial cells in a positive or negative fashion: mutation of the C-terminal tyrosine residues 13-16 (Y1311, Y1347, Y1354, and Y1363) reduced or abolished ligand-induced cell motility and branching morphogenesis. In contrast, mutation of the juxtamembrane tyrosine residue 2 (Y1001) produced constitutively mobile, fibroblastoid cells. Furthermore, the gain-of-function mutation of tyrosine residue 2 suppressed the loss-of-function mutations of tyrosine residue 15 or 16. The opposite roles of the juxtamembrane and C-terminal tyrosine residues may explain the suggested dual function of the met receptor in both epithelial-mesenchymal interactions and tumor progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7708691      PMCID: PMC42265          DOI: 10.1073/pnas.92.7.2597

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  Hepatocyte growth factor--scatter factor: mitogen, motogen, and met.

Authors:  E Gherardi; M Stoker
Journal:  Cancer Cells       Date:  1991-06

2.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.

Authors:  C Ponzetto; A Bardelli; Z Zhen; F Maina; P dalla Zonca; S Giordano; A Graziani; G Panayotou; P M Comoglio
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

3.  The pathway to signal achievement.

Authors:  S E Egan; R A Weinberg
Journal:  Nature       Date:  1993-10-28       Impact factor: 49.962

4.  A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor.

Authors:  C Ponzetto; A Bardelli; F Maina; P Longati; G Panayotou; R Dhand; M D Waterfield; P M Comoglio
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

5.  Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

Authors:  P Longati; A Bardelli; C Ponzetto; L Naldini; P M Comoglio
Journal:  Oncogene       Date:  1994-01       Impact factor: 9.867

6.  The Met proto-oncogene mesenchymal to epithelial cell conversion.

Authors:  I Tsarfaty; S Rong; J H Resau; S Rulong; P P da Silva; G F Vande Woude
Journal:  Science       Date:  1994-01-07       Impact factor: 47.728

7.  Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells.

Authors:  G Shiota; D B Rhoads; T C Wang; T Nakamura; E V Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

8.  The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras.

Authors:  G Hartmann; K M Weidner; H Schwarz; W Birchmeier
Journal:  J Biol Chem       Date:  1994-09-02       Impact factor: 5.157

9.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

10.  Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development.

Authors:  E Sonnenberg; D Meyer; K M Weidner; C Birchmeier
Journal:  J Cell Biol       Date:  1993-10       Impact factor: 10.539

View more
  29 in total

1.  The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M Holgado-Madruga; I Royal; M A Naujokas; T M Fournier; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

2.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

3.  Exocyst is involved in cystogenesis and tubulogenesis and acts by modulating synthesis and delivery of basolateral plasma membrane and secretory proteins.

Authors:  J H Lipschutz; W Guo; L E O'Brien; Y H Nguyen; P Novick; K E Mostov
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

4.  Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage.

Authors:  David Tulasne; Julien Deheuninck; Filipe Calheiros Lourenco; Fabienne Lamballe; Zongling Ji; Catherine Leroy; Emilie Puchois; Anice Moumen; Flavio Maina; Patrick Mehlen; Véronique Fafeur
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

5.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

6.  Positive and negative tissue-specific signaling by a nematode epidermal growth factor receptor.

Authors:  G M Lesa; P W Sternberg
Journal:  Mol Biol Cell       Date:  1997-05       Impact factor: 4.138

7.  Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.

Authors:  M Jeffers; G A Taylor; K M Weidner; S Omura; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

Review 8.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

9.  Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.

Authors:  J Voortman; T Harada; R P Chang; J K Killian; M Suuriniemi; W I Smith; P S Meltzer; M Lucchi; Y Wang; G Giaccone
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 10.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.